Maria Dorobanțu *, Florentina Mehic *, Elisabeta Badilă *, Daniela Bartoș *
* Prof. Dr. Maria Dorobanțu, Dr. Florentina Mehic, Dr. Elisabeta Badilă, Dr. Daniela Bartoș – Clinica de Medicină Internă și Cardiologie, Spitalul Clinic de Urgență “Floreasca”, București
Abstract
As a first choice therapy in treatment of community-acquired pneumonia in adults, international guideslines recommend macrolides in monotherapy (for younger patients or over 60 without others disease) or in asociation with cephalosporine of third generation or b-lactam (for inpatients). The objectives of this study is to assess the efficacy and safety of Azithromycin-a novel semisynthetic macrolide in treatment of community-acquiredpneumonia. There was included 20 patients with ages between 18 – 82 years, which were treated with Azithromycinin monotherapy (500 mg/day, 3 days) or in asociation with others antibiotics: Augmentin, Fortum, Penicilin G. We evaluate the evolution of symptoms, leucocitosis , radiological changes, the compliance with therapy and the duration of hospital admittance. The results show that the evolution was very good clinical and radiological; there was no adverse effects. Also, due to 3 days dosing regimen of Azithromycin,the duration of hospital admittance decrease. In conclusion, Azithromycin is an antibiotic of first choice in treatment of mild and moderate community-acquired pneumonia.
